Paramutation is a particular epigenetic phenomenon discovered in Zea mays by Alexander Brink in the 1950s, and then also found in other plants and animals. Brink coined the term paramutation (from the Greek syllable "para" meaning beside, near, beyond, aside) in 1958, with the aim to differentiate paramutation from mutation. The peculiarity of paramutation with respect to other gene silencing phenomena consists in the ability of the silenced allele (named paramutagenic) to silence the other allele (paramutable) present in trans. The newly silenced (paramutated) allele remains stable in the next generations even after segregation from the paramutagenic allele and acquires paramutagenic ability itself. The inheritance behaviour of these epialleles permits a fast diffusion of a particular gene expression level/phenotype in a population even in the absence of other evolutionary influences, thus breaking the Hardy-Weinberg law. As with other gene silencing phenomena such as quelling in the fungus Neurospora crassa, transvection in Drosophila, co-suppression and virus-induced gene silencing (VIGS) described in transgenic plants and RNA interference (RNAi) in the nematode Caenorhabditis elegans, paramutation occurs without changes in the DNA sequence. So far the molecular basis of paramutation remains not fully understood, although many studies point to the involvement of RNA causing changes in DNA methylation and chromatin structure of the silenced genes. In this review I summarize all paramutation phenomena described in plants, focusing on the similarities and differences between them.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.semcdb.2015.08.015 | DOI Listing |
Nucleic Acids Res
January 2025
Department of Biochemistry, University of Zurich, Winterthurerstrass 190, 8057 Zurich, Switzerland.
Type III clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) systems (type III CRISPR-Cas systems) use guide RNAs to recognize RNA transcripts of foreign genetic elements, which triggers the generation of cyclic oligoadenylate (cOA) second messengers by the Cas10 subunit of the type III effector complex. In turn, cOAs bind and activate ancillary effector proteins to reinforce the host immune response. Type III systems utilize distinct cOAs, including cyclic tri- (cA3), tetra- (cA4) and hexa-adenylates (cA6).
View Article and Find Full Text PDFNucleic Acids Res
January 2025
Research Center for Life Sciences Computing, Zhejiang Lab, Kechuang Avenue, Yuhang District, Hangzhou, Zhejiang, 311121, China.
The CRISPR-derived endoribonuclease Csy4 is a popular tool for controlling transgene expression in various therapeutically relevant settings, but adverse effects potentially arising from non-specific RNA cleavage remains largely unexplored. Here, we report a split-Csy4 architecture that was carefully optimized for in vivo usage. First, we separated Csy4 into two independent protein moieties whose full catalytic activity can be restored via various constitutive or conditional protein dimerization systems.
View Article and Find Full Text PDFElife
January 2025
Center for Medical Genetics Ghent, Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Heritable fragile bone disorders (FBDs), ranging from multifactorial to rare monogenic conditions, are characterized by an elevated fracture risk. Validating causative genes and understanding their mechanisms remain challenging. We assessed a semi-high throughput zebrafish screening platform for rapid in vivo functional testing of candidate FBD genes.
View Article and Find Full Text PDFCirc Res
January 2025
School of Basic Medical Sciences, Institute of Cardiovascular Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Health Science Center, Beijing, China. (Z.L., L.Y., Y.Y., J.L., Z.C., C.G., Y.G.).
Narra J
December 2024
Animal Research Facilities, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease 9 (CRISPR/Cas9) offers a robust approach for genome manipulation, particularly in cancer therapy. Given its high expression in triple-negative breast cancer (TNBC), targeting with CRISPR/Cas9 holds promise as a therapeutic strategy. The aim of this study was to design specific single guide ribonucleic acid (sgRNA) for CRISPR/Cas9 to permanently knock out the gene, exploring its potential as a therapeutic approach in breast cancer while addressing potential off-target effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!